CCM
VKTX icon

CAAS Capital Management’s Viking Therapeutics VKTX Stock Holding History

CAAS Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$1.04M Buy
43,207
+26,000
+151% +$822K 0.11% 177
2024
Q4 		$692K Hold
17,207
– – 0.12% 138
2024
Q3 		$1.09M Hold
17,207
– – 0.13% 141
2024
Q2 		$912K Sell
17,207
-15,793
-48% -$1.04M 0.29% 74
2024
Q1 		$2.71M Buy
+33,000
New +$1.47M 0.2% 128

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAAS Capital Management's VKTX Position: Q1 2025 in Review

CAAS Capital Management increased its Viking Therapeutics (VKTX) stake by 151% in Q1 2025, buying an estimated $822K and bringing the position to 43,207 shares worth $1.04M. The position accounts for 0.11% of the portfolio, ranked #177.

CAAS Capital Management first reported a position in VKTX in Q1 2024 and has held it in 5 quarters since. The position peaked at $2.71M in Q1 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • CAAS Capital Management held 43,207 shares of Viking Therapeutics worth $1.04M as of Q1 2025.
  • CAAS Capital Management bought 26,000 Viking Therapeutics shares in Q1 2025, an estimated $822K.
  • Viking Therapeutics made up 0.11% of CAAS Capital Management's portfolio in Q1 2025, its #177 holding.
  • CAAS Capital Management first reported a position in Viking Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • CAAS Capital Management's Viking Therapeutics position peaked at $2.71M in Q1 2024.
  • 372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on CAAS Capital Management's 13F filing for Q1 2025, filed 1 May 2025.